ImClone Systems Incorporated, Bristol-Myers Squibb Company Withdraw FDA Application

January 23, 2009 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Drug developers ImClone Systems and Bristol-Myers Squibb Co. said Friday they decided to withdraw an Erbitux supplemental biologics license application for advanced non-small cell lung cancer.

Twitter
LinkedIn
Facebook
Email
Print

Regulatory

Bristol Myers Squibb Company Food and Drug Administration (FDA)